Cel-Sci Corporation

Cel-Sci Corporation Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Cel-Sci Corporation, Medical Service, 8229 Boone Boulevard, Suite 802, Vienna, VA.

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

Geert Kersten, CEO of CEL-SCI, discusses the innovative approach of using immunotherapy, specifically Multikine, in canc...
09/24/2025

Geert Kersten, CEO of CEL-SCI, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer treatment. He emphasizes the importance of the immune system in fighting cancer and the need for a paradigm shift in how cancer therapies are developed and administered.

In this episode of Drug Diaries, Geert Kersten, CEO of Cel-Sci, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer t...

Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient...
08/13/2025

Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head &...
07/11/2025

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multik...
06/18/2025

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ...
05/21/2025

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI’S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
05/15/2025

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI reports fiscal second quarter 2025 financial results.

Geert Kersten, CEO of CEL-SCI, was interviewed on Fox News:
05/12/2025

Geert Kersten, CEO of CEL-SCI, was interviewed on Fox News:

Learn about the cutting-edge medical research happening at CEL-SCI—and how it’s changing the future of cancer immunotherapy.www.cel-sci.com

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia
04/23/2025

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia

CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market

A third-party head and neck cancer study published in “Cancer Cell” confirms the observation that pre-surgical tumor res...
04/08/2025

A third-party head and neck cancer study published in “Cancer Cell” confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival

New study in the scientific journal “Cancer Cell” supports CEL-SCI’s strategy to seek early approval for Multikine.

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Nec...
03/24/2025

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested...
03/17/2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.

JAMA Study Provides Further Evidence that Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expres...
03/14/2025

JAMA Study Provides Further Evidence that Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Address

8229 Boone Boulevard, Suite 802
Vienna, VA
22182

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+17035069460

Website

Alerts

Be the first to know and let us send you an email when Cel-Sci Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category